Neuromyelitis optica

Weiterbildungsziele

Differenzialdiagnostische Erkennung und diagnostische Einordnung der Neuromyelitis optica und ihrer Unterformen Pathophysiologisches Verständnis der Neuromyelitis optica Verständnis der Rolle von Aquaporin-4-Antikörpern Übersicht über die aktuellen Therapiemöglichkeiten

Literatur

• 1 Devic E. Subacute myelitis complicated by optic neuritis [in Französisch].  Bull Med. 1894;  8 1033-1034
• 2 Devic E. Acute dorsolumbar myelitis with optic neuritis, autopsy [in Französisch].  Congress Francais Medicine. 1895;  1 434-439
• 3 Albutt T. On the ophtalmoscopic signs of spinal disease.  Lancet. 1870;  1 76-88
• 4 Erb W. Über das Zusammenkommen von Neuritis optica und Myelitis subacuta.  Arch Psychiatr Nervenkr. 1879;  1 146-157
• 5 Phillips P H, Newman N J, Lynn M J. Optic Neuritis in African Americans.  Arch Neurol. 1998;  55 186-192
• 6 Gangopadhyay G, Das S, Sarda P. et al . Clinical profile of multiple sclerosis in Bengal.  Neurology India. 1999;  47 18-21
• 7 Kira J. Multiple sclerosis in the Japanese population.  Lancet Neurol. 2003;  2 117-127
• 8 Lau K, Wong L, Li L. et al . Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey.  Hong Kong Med J. 2002;  8 77-80
• 9 Wingerchuk D M, Hogancamp W F, O'Brien P C. et al . The clinical course of neuromyelitis optica (Devic's syndrome).  Neurology. 1999;  53 1107-1114
• 10 Jarius S, Wildemann B. Neuromyelitis optica.  Der Nervenarzt. 2007;  78 1365-1377
• 11 Wingerchuk D, Lennon V, Lucchinetti C. et al . The spectrum of neuromyelitis optica.  Lancet Neurol. 2007;  6 805-815
• 12 Wingerchuk D M, Lennon V A, Pittock S J. et al . Revised diagnostic criteria for neuromyelitis optica.  Neurology. 2006;  66 1485-1489
• 13 Jeffery A, Buncic J. Pediatric Devic's neuromyelitis optica.  J Pediatr Ophthalmol Strabismus. 1996;  33 223-239
• 14 Filley C, Sternberg P, Norenberg M. Neuromyelitis optica in the elderly.  Arch Neurol. 1984;  41 670-672
• 15 McKeon A, Lennon V A, Lotze T. et al . CNS aquaporin-4 autoimmunity in children.  Neurology. 2008;  71 93-100
• 16 Weinshenker B, Wingerchuk D, Nakashima I. et al . OSMS is NMO, but not MS: proven clinically and pathologically.  Lancet Neurol. 2006;  5 110-111
• 17 Yamasaki K, Horiuchi I, Minohara M. et al . HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.  Brain. 1999;  122 1689-1696
• 18 Pittock S J, Lennon V A, Krecke K. et al . Brain abnormalities in neuromyelitis optica.  Arch Neurol. 2006;  63 390-396
• 19 Jarius S, Paul F, Franciotta D. et al . Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.  Nat Clin Pract Neuro. 2008;  4 202-214
• 20 Misu T, Fujihara K, Nakashima I. et al . Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica.  Neurology. 2005;  65 1479-1482
• 21 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica: Clinical predictors of a relapsing course and survival.  Neurology. 2003;  60 848-853
• 22 Pittock S, Weinshenker B, Wijdicks E. Mechanical ventilation and tracheostomy in multiple sclerosis.  Neurol Neurosurg Psychiatry. 2004;  75 1331-1333
• 23 Howard R, Wiles C, Hirsch N. et al . Respiratory involvement in multiple sclerosis.  Brain. 1992;  115 479-494
• 24 Pittock S. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression.  Arch Neurol. 2006;  63 964-968
• 25 Vernant J, Cabre P, Smadja D. et al . Recurrent optic neuromyelitis with endocrinopathies: a new syndrome.  Neurology. 1997;  48 58-64
• 26 Wingerchuk D. A secondary progressive clinical course is uncommon in neuromyelitis optica.  Neurology. 2007;  68 603-605
• 27 de Seze J. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.  J Neurol Sci. 2002;  197 57-61
• 28 Ghezzi A. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica.  J Neurol. 2004;  251 47-52
• 29 Filippi M, Rocca M. MR imaging of Devic's neuromyelitis optica.  Neurol Sci. 2004;  25 371-373
• 30 Lycklama G. Spinal-cord MRI in multiple sclerosis.  Lancet Neurol. 2000;  2 555-562
• 31 Tartaglino L. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters.  Radiology. 1995;  195 725-732
• 32 Cabrera-Gomez J A, Quevedo-Sotolongo L, Gonzalez-Quevedo A. et al . Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.  Mult Scler. 2007;  13 186-192
• 33 Poppe A, Lapierre Y, Melançon D. et al . Neuromyelitis optica with hypothalamic involvement.  Mult Scler. 2005;  11 617-621
• 34 Ebers G, Paty D. CSF electrophoresis in one thousand patients.  Can J Neurol Sci. 1980;  7 275-280
• 35 McLean B, Luxton R, Thompson E. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications.  Brain. 1990;  113 1269-1289
• 36 O'Riordan J. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.  J Neurol Neurosurg Psychiatry. 1996;  60 382-387
• 37 Bergamaschi R. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.  Mult Scler. 2004;  10 2-4
• 38 Melamud L, Madalena L, Facio M. et al . Cerebrospinal fluid findings in Devic's neuromyelitis optica.  Mult Scler. 2006;  12 P246
• 39 Reiber H. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.  Mult Scler. 1998;  4 111-117
• 40 Meinl E. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.  Ann Neurol. 2006;  59 880-892
• 41 Satoh J. Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis.  J Neurol Sci. 2003;  212 11-20
• 42 Lennon V. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.  Lancet. 2004;  364 2106-2112
• 43 Jarius S. NMO-IgG in the diagnosis of neuromyelitis optica.  Neurology. 2007;  68 1076-1077
• 44 Lennon V. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.  J Exp Med. 2005;  202 473-477
• 45 Paul F. Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica.  PLoS Med. 2007;  4 e133
• 46 Nakashima I. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.  J Neurol Neurosurg Psychiatry. 2006;  77 1073-1075
• 47 Weinstock-Guttman B, Miller C, Yeh E. et al . Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.  Multiple Sclerosis. 2008;  14 1061-1067
• 48 Jung J. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance.  Proc Natl Acad Sci USA. 1994;  91 13 052-13 056
• 49 Roemer S F, Parisi J E, Lennon V A. et al . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.  Brain. 2007;  130 1194-1205
• 50 Manley G. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke.  Nat Med. 2000;  6 159-163
• 51 Amiry-Moghaddam M. Delayed K+ clearance associated with aquaporin-4 mislocalization: phenotypic defects in brains of [alpha]-syntrophin-null mice.  Proc Natl Acad Sci USA. 2003;  100 13 615-13 620
• 52 Takahashi T, Fujihara K, Nakashima I. et al . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.  Brain. 2007;  130 1235-1243
• 53 Waters P. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally-extensive transverse myelitis.  Arch Neurol. 2008;  65 913-919
• 54 Lalive P. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.  Neurology. 2006;  67 176-177
• 55 Lucchinetti C F, Mandler R N, McGavern D. et al . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.  Brain. 2002;  125 1450-1461
• 56 Holley J. Astrocyte characterization in the multiple sclerosis glial scar.  Neuropathol Appl Neurobiol. 2003;  29 434-444
• 57 Ayers M. Early glial responses in murine models of multiple sclerosis.  Neurochem Int. 2004;  45 409-419
• 58 Pittock S, Lennon V. Aquaporin-4 autoantibodies in a paraneoplastic context.  Arch Neurol. 2008;  65 629-632
• 59 Misu T, Fujihara K, Kakita A. et al . Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.  Brain. 2007;  130 1224-1234
• 60 Matiello M, Lennon V A, Jacob A. et al . NMO-IgG predicts the outcome of recurrent optic neuritis.  Neurology. 2008;  70 2197-2200
• 61 Paty D, Oger J, Kastrukoff L. et al . MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.  Neurology. 1988;  38 180-185
• 62 Barkhof F, Filippi M, Miller D. et al . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.  Brain. 1997;  120 2059-2069
• 63 Wingerchuk D. Diagnosis and treatment of neuromyelitis optica.  Neurologist. 2007;  13 2-11
• 64 Weinshenker B, Wingerchuk D, Vukusic S. et al . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.  Ann Neurol. 2006;  59 566-569
• 65 Jacobi C. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus.  Lupus. 2006;  15 107-109
• 66 Weinshenker B, Pittock S, de Seze J. et al . The relationship between neuromyelitis optica and systemic auto-immune disease.  Mult Scler. 2006;  12 O79
• 67 Pittock S, Lennon V, de Seze J. et al . Neuromyelitis optica and non organ-specific autoimmunity.  Arch Neurol. 2008;  65 78-83
• 68 Wingerchuk D, Weinshenker B. Neuromyelitis optica.  Curr Treat Options Neurol. 2008;  10 55-66
• 69 Beck R W, Cleary P A, Trobe J D. et al . The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis.  N Engl J Med. 1993;  329 1764-1769
• 70 Keegan M, Pineda A A, McClelland R L. et al . Plasma exchange for severe attacks of CNS demyelination: Predictors of response.  Neurology. 2002;  58 143-146
• 71 Papeix C, Vidal J-S, de Seze J. et al . Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.  Multiple Sclerosis. 2007;  13 256-259
• 72 Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.  J Neurol Sci. 2007;  252 57-61
• 73 Saida T, Tashiro K, Itoyama Y. et al . Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study.  Neurology. 2005;  64 621-630
• 74 Bergamaschi R. Glatiramer acetate treatment in Devic's neuromyelitis optica.  Brain. 2003;  126 E1
• 75 Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.  Eur J Neurol. 2007;  14 12-13
• 76 Watanabe S, Misu T, Miyazawa I. et al . Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.  Mult Scler. 2007;  13 968-974
• 77 Mandler R. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.  Neurology. 1998;  51 1219-1220
• 78 Cree B AC, Lamb S, Morgan K. et al . An open label study of the effects of rituximab in neuromyelitis optica.  Neurology. 2005;  64 1270-1272
• 79 Jacob A, Weinshenker B G, Violich I. et al . Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients.  Arch Neurol. 2008;  65 noc80069
• 80 Chan A, Weilbach F, Toyka K. et al . Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.  Clin Exp Immunol. 2005;  139 152-158
• 81 Neuhaus O, Wiendl H, Kieseier B. et al . Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.  J Neuroimmunol. 2005;  1–2 128-137
• 82 Weinstock-Guttman B, Ramanathan M, Lincoff N. et al . Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).  Arch Neurol. 2006;  63 957-963
• 83 Falcini F, Trapani S, Ricci L. et al . Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.  Rheumatology. 2006;  45 913-915
• 84 Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).  Can J Neurol Sci. 2004;  31 265-267